We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Blood Sample to Diagnose TBI Severity Could Reduce Need for MRI Scan

By LabMedica International staff writers
Posted on 11 May 2022

Traumatic brain injury (TBI) is one of the most common neurological diseases worldwide affecting all ages and is commonly caused by a fall, road traffic accident or assault. More...

TBI is divided into three categories ranging from mild to severe, although no reliable methods exist for ruling out acute brain injury. Researchers have now identified biomarkers in the blood that can indicate how serious a head trauma is, enabling a simple blood sample to diagnose TBI severity.

Researchers at Örebro University (Örebro, Sweden) who have been working on a non-surgical procedure to diagnose TBI severity used blood samples collected by EU project CENTER-TBI - the largest study of its kind. The EU project CENTER-TBI currently prospectively collects clinical data including records from 5,400 patients, files of imaging workup as well as blood samples from TBI patients from 60 sites of 18 countries. The overall objective is to apply metabolic profiling of serum in the CENTER-TBI cohort to study the utility of the existing as well as to identify novel biomarkers of TBI which are also predictive of patient outcomes.

Using metabolomics - a chemical analysis method to extract information about thousands of small molecules - the Örebro researchers have identified biomarkers that can be linked to TBI. With the help of these biomarkers, healthcare providers will not only be able to assess the severity of the injury but also predict the patient outcome. Healthcare providers will be able to categorize the injuries more clearly by simply taking a blood sample which is cost-effective, simpler and safer for the patient and eliminates the need for an MRI scan.

Related Links:
Örebro University 


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
POC Immunoassay Analyzer
Procise DX
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.